Johnson & Johnson $JNJ Shares Sold by D L Carlson Investment Group Inc.

Key Points

• D L Carlson Investment Group Inc. reduced its position in Johnson & Johnson by 6.0%, selling 2,109 shares, and now holds 32,836 shares valued at approximately $5.45 million.
• The company reported earnings of $2.77 per share for the last quarter, exceeding estimates, with a revenue of $23.74 billion, demonstrating a year-over-year growth of 5.8%.
• Johnson & Johnson declared a quarterly dividend of $1.30, resulting in an annualized dividend of $5.20 and a dividend yield of 2.9%, with a payout ratio of 55.61%.

D L Carlson Investment Group Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,836 shares of the company's stock after selling 2,109 shares during the period. Johnson & Johnson makes up about 1.0% of D L Carlson Investment Group Inc.'s investment portfolio, making the stock its 22nd largest position. D L Carlson Investment Group Inc.'s holdings in Johnson & Johnson were worth $5,445,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Hudson Value Partners LLC increased its stake in Johnson & Johnson by 2.5% in the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares in the last quarter. Bellwether Advisors LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth about $97,000. Perbak Capital Partners LLP acquired a new stake in Johnson & Johnson during the 4th quarter worth about $1,554,000. Finally, AQR Capital Management LLC boosted its position in Johnson & Johnson by 9.9% during the 4th quarter. AQR Capital Management LLC now owns 3,472,635 shares of the company's stock worth $500,094,000 after acquiring an additional 313,672 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 1.0%

NYSE:JNJ opened at $176.63 on Wednesday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The business's 50-day moving average price is $164.44 and its two-hundred day moving average price is $159.60. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $425.39 billion, a price-to-earnings ratio of 18.89, a PEG ratio of 2.27 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the firm posted $2.82 earnings per share. The company's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JNJ. Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. UBS Group lifted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Morgan Stanley boosted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Barclays boosted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Finally, Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.